ClinicalTrials.gg
CompletedNCT01724866Updated Apr 15, 2022Results posted

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

A Phase 2 interventional study of SPI-2012 and Pegfilgrastim in Neutropenia, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
13th of 28
148 · median 121
Started
2013
with 1 other
Phase 2
14 of 33
none open now
Registered
21st of 33
by date
Lead sponsor
3 of 33
Spectrum Pharmaceuticals, Inc

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 2, and was the 21st registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.

Read the detailed description

This is an open label, multicenter, dose ranging study, sequentially enrolled by study dose, with a non-inferiority design to compare the effectiveness of SPI-2012 relative to a fixed dose of pegfilgrastim as a concurrent active control to each dose of SPI-2012 in participants with breast cancer. This study included four arms comprising three dose levels of SPI-2012 (Arm 1: 45 µg/kg, Arm 2: 135 µg/kg, Arm 3: 270 µg/kg) versus pegfilgrastim (Arm 4: 6 mg). The start of study is defined as the initiation of treatment with SPI-2012 or pegfilgrastim. The duration of treatment consists of a maximum of 4 cycles (21 days per cycle) beginning on Day 1 with chemotherapy administration and continue through Day 21, plus a 30-day follow-up period, unless any of the discontinuation criteria applies.

The target population are participants with breast cancer who are candidates for neoadjuvant or adjuvant treatment with Docetaxel + Cyclophosphamide (TC) chemotherapy. All participants who receive at least 1 dose of either SPI-2012 or pegfilgrastim were followed for safety through 30 days after their last dose of study treatment or until all treatment-related adverse events (AEs) have resolved or returned to baseline/Grade 1, whichever is longer, or until it is determined that the outcome will not change with further follow-up.

03

Conditions studied

  • Neutropenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed breast cancer and candidate for or neoadjuvant chemotherapy
  • Candidate for docetaxel and cyclophosphamide chemotherapy
  • Female or male at least 18 years of age
  • (ECOG) ≤ 2
  • (ANC) ≥ 1.5×109/L
  • count ≥ 100 x 10\^9/L
  • Creatinine ≤ 1.5 x (ULN)
  • Total ≤1.5 mg/dL(≤ 25.65 μmol/L).
  • per serum glutamic-oxaloacetic transaminase (AST/SGOT) and/or alanine aminotransferase per serum glutamic-pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN
  • > 9 g/dL
  • Alkaline phosphatase ≤ 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Known sensitivity to E. coli-derived products or known sensitivity to any of the products to be administered
  • Known (HIV) infection
  • Virus (HBV) or Virus (HCV) diagnosis with detectable viral load or immunological evidence of chronic active disease
  • Active infection or any serious underlying medical condition that would impair ability to receive protocol treatment
  • Prior bone marrow or stem cell transplant
  • Prolonged exposure to glucocorticosteroids and agents
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)

    Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 milligram/ square metre (mg/m\^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.

    Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide

  • Experimental
    Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC)

    Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.

    Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide

  • Experimental
    Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC)

    Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.

    Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide

  • Experimental
    Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)

    Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.

    Drug: Pegfilgrastim · Drug: Docetaxel · Drug: Cyclophosphamide

Interventions

  • SPI-2012 SC injection.

    Also known as: Rolontis®, HM10460A, Eflapegrastim

  • Pegfilgrastim SC injection, per manufacturer's Prescribing Information.

    Also known as: Neulasta®

  • Docetaxel given based on standard dose for chemotherapy.

    Also known as: Taxotere

  • Cyclophosphamide given based on standard dose for chemotherapy.

    Also known as: Cytoxan

06

What researchers measure

Primary outcomes

  1. Duration of Severe Neutropenia (DSN) in Cycle 1

    DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 1.

    Time frame: Cycle 1 (each cycle was 21 days)

Secondary outcomes

  1. Duration of DSN in Cycle 2

    DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 2.

    Time frame: Cycle 2 (each cycle was 21 days)

  2. Duration of DSN in Cycle 3

    DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 3.

    Time frame: Cycle 3 (each cycle was 21 days)

  3. Duration of DSN in Cycle 4

    DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 4.

    Time frame: Cycle 4 (each cycle was 21 days)

  4. Time to ANC Recovery in Cycle 1

    Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥ 2×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 1.

    Time frame: Cycle 1 (each cycle was 21 days)

  5. Time to ANC Recovery in Cycle 2

    Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 2. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 2.

    Time frame: Cycle 2 (each cycle was 21 days)

  6. Time to ANC Recovery in Cycle 3

    Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 3. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 3.

    Time frame: Cycle 3 (each cycle was 21 days)

  7. Time to ANC Recovery in Cycle 4

    Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 4. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 4.

    Time frame: Cycle 4 (each cycle was 21 days)

  8. Absolute Neutrophil Count (ANC) Nadir Overtime in Cycle 1

    Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.

    Time frame: Cycle 1 (each cycle was 21 days)

  9. Absolute ANC Nadir Overtime in Cycle 2

    Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.

    Time frame: Cycle 2 (each cycle was 21 days)

  10. Absolute ANC Nadir Overtime in Cycle 3

    Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.

    Time frame: Cycle 3 (each cycle was 21 days)

  11. Absolute ANC Nadir Overtime in Cycle 4

    Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.

    Time frame: Cycle 4 (each cycle was 21 days)

  12. Depth of ANC Nadir in Cycle 1

    Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.

    Time frame: Cycle 1 (each cycle was 21 days)

  13. Depth of ANC Nadir in Cycle 2

    Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.

    Time frame: Cycle 2 (each cycle was 21 days)

  14. Depth of ANC Nadir in Cycle 3

    Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.

    Time frame: Cycle 3 (each cycle was 21 days)

  15. Depth of ANC Nadir in Cycle 4

    Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.

    Time frame: Cycle 4 (each cycle was 21 days)

  16. Time to ANC Nadir in Cycle 1

    Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

    Time frame: Cycle 1 (each cycle was 21 days)

  17. Time to ANC Nadir in Cycle 2

    Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

    Time frame: Cycle 2 (each cycle was 21 days)

  18. Time to ANC Nadir in Cycle 3

    Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

    Time frame: Cycle 3 (each cycle was 21 days)

  19. Time to ANC Nadir in Cycle 4

    Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

    Time frame: Cycle 4 (each cycle was 21 days)

  20. Percentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 4

    FN was defined as a temperature of more than 38.2 degree Celsius (°C) concurrent with an ANC greater than 0.5×10\^9/L..

    Time frame: Cycle 1 to Cycle 4 (each cycle was 21 days)

  21. Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Other Serious Adverse Events (SAEs), and Other AEs Leading to Discontinuation From Study Therapy, and Worst Grade Laboratory Abnormalities

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Participants with SAE other than death were reported.AE and Laboratory Abnormalities ("Hematology and Chemistry") were collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated and Grade 4 refers to life-threatening consequences; urgent intervention indicated.

    Time frame: From the first dose up to 30 days post last dose of study drug (up to 4 months)

  22. Percentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 4

    Time frame: All cycles from Cycle 1 to Cycle 4 (each cycle was 21 days)

  23. Number of Participants With Positive Antibodies for SPI-2012

    Serum samples were to be tested in a screening assay for antibodies binding to SPI-2012 using a validated enzyme-linked immunosorbent assay (ELISA). Any serum samples positive for the antibody were to be tested in a confirmatory competitive inhibition assay using two antigens, SPI-2012 or granulocyte colony-stimulating factor (G-CSF), to confirm the presence of antibodies binding to SPI-2012 and to identify samples that were positive for antibodies binding to G-CSF.

    Time frame: Up to the end of the study (Approximately 3.5 months)

  24. Time to Reach Maximum Concentration of SPI-2012 (Tmax)

    Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive pharmacokinetic (PK) parameters.

    Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)

  25. Maximum Concentration of SPI-2012 (Cmax)

    Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

    Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)

  26. Area Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312)

    AUC(0-312) is the area under the serum concentration-time curve from time zero to 312 hour post dose calculated by the linear trapezoidal rule. Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

    Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)

  27. Half-life of SPI-2012 (t1/2)

    t1/2 data were calculated and reported as harmonic mean and pseudo standard deviation (SD). Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

    Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)

07

Results

Posted Apr 15, 2022

Participant flow

Participants were enrolled at 27 investigative sites in the United States (10 sites), Australia (5 sites), Georgia (2 sites), Hungary (5 sites), Israel (1 site), and Poland (4 sites) from 25 March 2013 to 12 August 2014.

Participant flow — Overall Study
MilestoneArm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)Arm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Started39373636
Evaluable population39363636
Completed38323335
Not completed1531
Withdrew: Adverse event0011
Withdrew: Initiation of non-protocol therapy either for progressive disease or intolerance of tc regimen0200
Withdrew: Investigator's discretion0110
Withdrew: Need for chemotherapy or chemotherapy regimen was changed due to amended her2 status1000
Withdrew: Participant refused further treatment or withdrew consent0210

Outcome measures

PrimaryDuration of Severe Neutropenia (DSN) in Cycle 1

DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 1.

Time frame:
Cycle 1 (each cycle was 21 days)
Reported as:
Mean · days
Duration of Severe Neutropenia (DSN) in Cycle 1
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Duration of Severe Neutropenia (DSN) in Cycle 11.03 ± 1.5470.44 ± 1.2750.03 ± 0.1670.31 ± 0.822
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = 0.296 · Mean difference (final values): 0.72 · 95% CI 0.19 to 1.27
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = 0.002 · Mean difference (final values): 0.14 · 95% CI -0.28 to 0.64
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): -0.28 · 95% CI -0.56 to -0.06
SecondaryDuration of DSN in Cycle 2

DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 2.

Time frame:
Cycle 2 (each cycle was 21 days)
Reported as:
Mean · days
Duration of DSN in Cycle 2
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Duration of DSN in Cycle 20.46 ± 1.0220.12 ± 0.4780.03 ± 0.1710.08 ± 0.368
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = 0.001 · Mean difference (final values): 0.38 · 95% CI 0.06 to 0.74
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): 0.04 · 95% CI -0.16 to 0.24
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): -0.05 · 95% CI -0.19 to 0.06
SecondaryDuration of DSN in Cycle 3

DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 3.

Time frame:
Cycle 3 (each cycle was 21 days)
Reported as:
Mean · days
Duration of DSN in Cycle 3
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Duration of DSN in Cycle 30.45 ± 1.1320.16 ± 0.6280.15 ± 0.6100.14 ± 0.593
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = 0.002 · Mean difference (final values): 0.31 · 95% CI -0.07 to 0.72
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): 0.02 · 95% CI -0.27 to 0.30
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): 0.01 · 95% CI -0.27 to 0.28
SecondaryDuration of DSN in Cycle 4

DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 4.

Time frame:
Cycle 4 (each cycle was 21 days)
Reported as:
Mean · days
Duration of DSN in Cycle 4
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Duration of DSN in Cycle 41.05 ± 4.5790.19 ± 0.7380.09 ± 0.5220.11 ± 0.404
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = 0.781 · Mean difference (final values): 0.94 · 95% CI -0.01 to 2.47
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): 0.07 · 95% CI -0.17 to 0.38
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Bootstrap method · p = <0.001 · Mean difference (final values): -0.02 · 95% CI -0.23 to 0.22
SecondaryTime to ANC Recovery in Cycle 1

Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥ 2×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 1.

Time frame:
Cycle 1 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Recovery in Cycle 1
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Recovery in Cycle 110.0 (10.0 to 11.0)8.5 (8.0 to 9.0)8.0 (7.0 to 9.0)9.0 (8.0 to 10.0)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.002 · Hazard ratio (hr): 1.4 · 95% CI 1.1 to 1.8
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.711 · Hazard ratio (hr): 0.9 · 95% CI 0.6 to 1.4
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.028 · Hazard ratio (hr): 0.3 · 95% CI 0.1 to 0.9
SecondaryTime to ANC Recovery in Cycle 2

Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 2. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 2.

Time frame:
Cycle 2 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Recovery in Cycle 2
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Recovery in Cycle 211.0 (10.0 to 11.0)9.5 (8.0 to 10.0)10.0 (8.0 to 14.0)10.0 (8.0 to 11.0)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.672 · Hazard ratio (hr): 1.1 · 95% CI 0.8 to 1.4
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.348 · Hazard ratio (hr): 0.8 · 95% CI 0.5 to 1.3
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.973 · Hazard ratio (hr): 1.1 · 95% CI 0.4 to 2.9
SecondaryTime to ANC Recovery in Cycle 3

Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 3. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 3.

Time frame:
Cycle 3 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Recovery in Cycle 3
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Recovery in Cycle 310.0 (10.0 to 11.0)9.5 (8.0 to 12.0)9.0 (8.0 to 13.0)10.0 (9.0 to 11.0)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.618 · Hazard ratio (hr): 1.1 · 95% CI 0.8 to 1.4
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.661 · Hazard ratio (hr): 0.9 · 95% CI 0.5 to 1.6
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.754 · Hazard ratio (hr): 0.9 · 95% CI 0.3 to 2.8
SecondaryTime to ANC Recovery in Cycle 4

Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 4. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 4.

Time frame:
Cycle 4 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Recovery in Cycle 4
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Recovery in Cycle 411.0 (10.0 to 13.0)10.0 (9.0 to 11.0)10.0 (8.0 to 14.0)10.0 (8.0 to 11.0)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.009 · Hazard ratio (hr): 1.4 · 95% CI 1.1 to 1.7
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.527 · Hazard ratio (hr): 1.1 · 95% CI 0.7 to 1.8
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Log Rank · p = 0.815 · Hazard ratio (hr): 1.2 · 95% CI 0.4 to 3.9
SecondaryAbsolute Neutrophil Count (ANC) Nadir Overtime in Cycle 1

Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.

Time frame:
Cycle 1 (each cycle was 21 days)
Reported as:
Mean · 10^9 ANC per liter
Absolute Neutrophil Count (ANC) Nadir Overtime in Cycle 1
10^9 ANC per literArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Absolute Neutrophil Count (ANC) Nadir Overtime in Cycle 11.5 ± 1.774.0 ± 3.867.2 ± 5.473.2 ± 2.43
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.008P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.911P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.002P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
SecondaryAbsolute ANC Nadir Overtime in Cycle 2

Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.

Time frame:
Cycle 2 (each cycle was 21 days)
Reported as:
Mean · 10^9 ANC/L
Absolute ANC Nadir Overtime in Cycle 2
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Absolute ANC Nadir Overtime in Cycle 22.0 ± 1.893.9 ± 2.556.8 ± 6.303.3 ± 2.16
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.005P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.633P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.027P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
SecondaryAbsolute ANC Nadir Overtime in Cycle 3

Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.

Time frame:
Cycle 3 (each cycle was 21 days)
Reported as:
Mean · 10^9 ANC/L
Absolute ANC Nadir Overtime in Cycle 3
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Absolute ANC Nadir Overtime in Cycle 32.3 ± 1.874.4 ± 3.266.1 ± 4.813.5 ± 1.92
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.015P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.571P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.066P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
SecondaryAbsolute ANC Nadir Overtime in Cycle 4

Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.

Time frame:
Cycle 4 (each cycle was 21 days)
Reported as:
Mean · 10^9 ANC/L
Absolute ANC Nadir Overtime in Cycle 4
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Absolute ANC Nadir Overtime in Cycle 42.1 ± 2.124.1 ± 2.864.8 ± 3.002.7 ± 1.64
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.106P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.156P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Asymptotic Normality Assumption · p = 0.005P-values was obtained based upon asymptotic normality assumption on the log10 transformed data.
SecondaryDepth of ANC Nadir in Cycle 1

Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.

Time frame:
Cycle 1 (each cycle was 21 days)
Reported as:
Median · 10^9 ANC/L
Depth of ANC Nadir in Cycle 1
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Depth of ANC Nadir in Cycle 10.8 (0.0 to 9.0)3.0 (0.1 to 14.1)6.2 (0.2 to 21.0)3.0 (0.0 to 9.1)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 0.4 · 95% CI 0.25 to 0.80
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.0 · 95% CI 0.53 to 2.04
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 2.5 · 95% CI 1.40 to 4.54
SecondaryDepth of ANC Nadir in Cycle 2

Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.

Time frame:
Cycle 2 (each cycle was 21 days)
Reported as:
Median · 10^9 ANC/L
Depth of ANC Nadir in Cycle 2
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Depth of ANC Nadir in Cycle 21.3 (0.1 to 8.0)3.3 (0.1 to 9.5)4.8 (0.3 to 25.7)2.9 (0.1 to 9.2)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 0.5 · 95% CI 0.30 to 0.80
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.1 · 95% CI 0.70 to 1.79
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.7 · 95% CI 1.07 to 2.79
SecondaryDepth of ANC Nadir in Cycle 3

Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.

Time frame:
Cycle 3 (each cycle was 21 days)
Reported as:
Median · 10^9 ANC/L
Depth of ANC Nadir in Cycle 3
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Depth of ANC Nadir in Cycle 31.9 (0.0 to 7.3)3.4 (0.1 to 12.3)4.1 (0.2 to 21.4)3.5 (0.1 to 8.1)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 0.5 · 95% CI 0.34 to 0.89
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.1 · 95% CI 0.71 to 1.85
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.6 · 95% CI 0.97 to 2.49
SecondaryDepth of ANC Nadir in Cycle 4

Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.

Time frame:
Cycle 4 (each cycle was 21 days)
Reported as:
Median · 10^9 ANC/L
Depth of ANC Nadir in Cycle 4
10^9 ANC/LArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Depth of ANC Nadir in Cycle 48.0 (0.0 to 9.2)4.2 (0.1 to 11.2)4.2 (0.4 to 11.9)2.4 (0.1 to 6.4)
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 0.7 · 95% CI 0.40 to 1.10
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.4 · 95% CI 0.87 to 2.38
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Ratio: 1.9 · 95% CI 1.23 to 2.96
SecondaryTime to ANC Nadir in Cycle 1

Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

Time frame:
Cycle 1 (each cycle was 21 days)
Reported as:
Median · Days
Time to ANC Nadir in Cycle 1
DaysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Nadir in Cycle 18.0 (7.0 to 8.0)7.0 (7.0 to NA)7.0 (7.0 to 8.0)7.5 (7.0 to 16.0)
SecondaryTime to ANC Nadir in Cycle 2

Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

Time frame:
Cycle 2 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Nadir in Cycle 2
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Nadir in Cycle 28.0 (8.0 to NA)7.0 (7.0 to 8.0)8.0 (7.0 to 10.0)8.0 (7.0 to 15.0)
SecondaryTime to ANC Nadir in Cycle 3

Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

Time frame:
Cycle 3 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Nadir in Cycle 3
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Nadir in Cycle 38.0 (8.0 to NA)7.0 (7.0 to 8.0)8.0 (7.0 to 9.0)8.0 (7.0 to 15.0)
SecondaryTime to ANC Nadir in Cycle 4

Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.

Time frame:
Cycle 4 (each cycle was 21 days)
Reported as:
Median · days
Time to ANC Nadir in Cycle 4
daysArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Time to ANC Nadir in Cycle 48.0 (8.0 to NA)8.0 (7.0 to 8.0)8.0 (7.0 to 21.0)8.0 (7.0 to 8.0)
SecondaryPercentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 4

FN was defined as a temperature of more than 38.2 degree Celsius (°C) concurrent with an ANC greater than 0.5×10\^9/L..

Time frame:
Cycle 1 to Cycle 4 (each cycle was 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 4
percentage of participantsArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Percentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 47.72.82.85.6
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 1.000 · Percent difference: 2.1 · 95% CI -20.2 to 24.9
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 1.000 · Percent difference: -2.8 · 95% CI -26.7 to 21.4
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 1.000 · Percent difference: -2.8 · 95% CI -26.7 to 21.4
SecondaryNumber of Participants With Worst Grade Adverse Events (AEs), Deaths, Other Serious Adverse Events (SAEs), and Other AEs Leading to Discontinuation From Study Therapy, and Worst Grade Laboratory Abnormalities

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Participants with SAE other than death were reported.AE and Laboratory Abnormalities ("Hematology and Chemistry") were collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated and Grade 4 refers to life-threatening consequences; urgent intervention indicated.

Time frame:
From the first dose up to 30 days post last dose of study drug (up to 4 months)
Reported as:
Count of participants · Participants
Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Other Serious Adverse Events (SAEs), and Other AEs Leading to Discontinuation From Study Therapy, and Worst Grade Laboratory Abnormalities
ParticipantsArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Grade 3-4 TEAEs24121312
Death0000
SAEs Other Than Death5428
TEAEs Leading to Discontinuation From Study Therapy0211
Grade 3-4 Lab Abnormalities: Hematology33191828
Grade 3-4 Lab Abnormalities: Chemistry8468
SecondaryPercentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 4
Time frame:
All cycles from Cycle 1 to Cycle 4 (each cycle was 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 4
percentage of participantsArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
Percentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 47.78.32.813.9
Statistical analysis
  • Arm 1: SPI-2012 45 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 0.469 · Percent difference: -6.2 · 95% CI -28.5 to 16.9
  • Arm 2: SPI-2012 135 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 0.710 · Percent difference: -5.6 · 95% CI -29.3 to 18.7
  • Arm 3: SPI-2012 270 µg/kg and TC vs Arm 4: Pegfilgrastim and TC · Fisher Exact · p = 0.199 · Percent difference: -11.1 · 95% CI -34.6 to 13.3
SecondaryNumber of Participants With Positive Antibodies for SPI-2012

Serum samples were to be tested in a screening assay for antibodies binding to SPI-2012 using a validated enzyme-linked immunosorbent assay (ELISA). Any serum samples positive for the antibody were to be tested in a confirmatory competitive inhibition assay using two antigens, SPI-2012 or granulocyte colony-stimulating factor (G-CSF), to confirm the presence of antibodies binding to SPI-2012 and to identify samples that were positive for antibodies binding to G-CSF.

Time frame:
Up to the end of the study (Approximately 3.5 months)
Reported as:
Count of participants · Participants
Number of Participants With Positive Antibodies for SPI-2012
ParticipantsArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TC
Number of Participants With Positive Antibodies for SPI-2012002
SecondaryTime to Reach Maximum Concentration of SPI-2012 (Tmax)

Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive pharmacokinetic (PK) parameters.

Time frame:
Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Reported as:
Median · hours (hrs)
Time to Reach Maximum Concentration of SPI-2012 (Tmax)
hours (hrs)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TC
Time to Reach Maximum Concentration of SPI-2012 (Tmax)58.7 (46.9 to 70.5)9.00 (8 to 48.1)24.0 (24 to 24.1)
SecondaryMaximum Concentration of SPI-2012 (Cmax)

Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

Time frame:
Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Concentration of SPI-2012 (Cmax)
nanograms per milliliter (ng/mL)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TC
Maximum Concentration of SPI-2012 (Cmax)7.00 ± 6.08247 ± 276299 ± 329
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312)

AUC(0-312) is the area under the serum concentration-time curve from time zero to 312 hour post dose calculated by the linear trapezoidal rule. Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

Time frame:
Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312)
nanogram*hour per milliliter (ng*hr/mL)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TC
Area Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312)—16000 ± 585022900 ± 25100
SecondaryHalf-life of SPI-2012 (t1/2)

t1/2 data were calculated and reported as harmonic mean and pseudo standard deviation (SD). Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.

Time frame:
Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · hrs
Half-life of SPI-2012 (t1/2)
hrsArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TC
Half-life of SPI-2012 (t1/2)—81.0 ± 88.431.5 ± NA

Adverse events

Collected over From the first dose up to 30 days post last dose of study drug (up to 4 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: SPI-2012 45 µg/kg and TC0/39 (0%)5/39 (12.8%)36/39 (92.3%)
Arm 2: SPI-2012 135 µg/kg and TC0/37 (0%)4/37 (10.8%)33/37 (89.2%)
Arm 3: SPI-2012 270 µg/kg and TC0/36 (0%)2/36 (5.6%)33/36 (91.7%)
Arm 4: Pegfilgrastim and TC0/36 (0%)8/36 (22.2%)35/36 (97.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
PyrexiaGeneral disorders0/390/370/362/36
Febrile neutropeniaBlood and lymphatic system disorders2/391/371/361/36
Atrial fibrillationCardiac disorders0/390/370/361/36
DiverticulitisInfections and infestations1/390/371/360/36
Back painMusculoskeletal and connective tissue disorders0/390/370/361/36
Vaginal haemorrhageReproductive system and breast disorders0/390/370/361/36
UrticariaSkin and subcutaneous tissue disorders0/390/370/361/36
CellulitisInfections and infestations0/390/370/361/36
Non-cardiac chest painGeneral disorders0/391/370/360/36
Gastritis viralInfections and infestations0/391/370/360/36
Most frequent other events
Most frequent other events
EventArm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TC
FatigueGeneral disorders24/3911/3719/3620/36
AlopeciaSkin and subcutaneous tissue disorders21/3918/3712/3613/36
NauseaGastrointestinal disorders19/3912/3715/3616/36
DiarrhoeaGastrointestinal disorders17/397/3714/3615/36
Bone painMusculoskeletal and connective tissue disorders9/3910/3712/3613/36
HeadacheNervous system disorders12/395/378/369/36
InsomniaPsychiatric disorders3/395/375/3611/36
AstheniaGeneral disorders5/392/375/368/36

Baseline characteristics

The Evaluable Population included all randomized participants who had received either SPI-2012 or pegfilgrastim and had completed Cycle 1.

Age, Continuous
Age, Continuous(years)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TCTotal
Mean59.8 ± 11.3156.8 ± 10.6355.7 ± 9.7960.4 ± 10.4358.2 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TCTotal
Female39353436144
Male01203
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TCTotal
Hispanic or Latino622414
Not Hispanic or Latino33343432133
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: SPI-2012 45 µg/kg and TCArm 2: SPI-2012 135 µg/kg and TCArm 3: SPI-2012 270 µg/kg and TCArm 4: Pegfilgrastim and TCTotal
American Indian or Alaska Native10001
Asian00101
Black or African American20002
White36363532139
Others00044
08

Study locations

27 sites
  • Arizona Center for Cancer Care
    Glendale, Arizona 85306, United States
  • Desert Springs Cancer Care
    Scottsdale, Arizona 85255, United States
  • California Cancer Associates for Research and Excellence
    Fresno, California 93720, United States
  • Beaver Medical Group
    Highland, California 92346, United States
  • California Cancer Associates for Research and Excellence
    Los Angeles, California 92025, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • New York Oncology Hematology, PC
    Albany, New York 12206, United States
  • North Shore Hematology/Oncology Associates
    Setauket, New York 11733, United States
  • Good Samaritan Hospital, Corvallis
    Corvallis, Oregon 97330, United States
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Royal Hobart
    Brisbane, 7000, Australia
  • Ashford Cancer Center Research
    Kurralta Park, 5037, Australia
  • Breast Cancer Research Center, WA
    Perth, 6000, Australia
  • Ballarat Oncology & Haematology
    Wendouree, 3355, Australia
  • LTD " Cancer Center of Adjara Autonomic Republic"
    Batumi, 6000, Georgia
  • Ltd ' Medulla - Chemotherapy and Immunotherapy Clinic
    Tbilisi, 0186, Georgia
  • State Health Center
    Budapest, 1062, Hungary
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • Uzsoki Hospital
    Budapest, 1146, Hungary
  • University Debrecen, Oncology Clinic
    Debrecen, 4032, Hungary
  • Szabolcs - Szatmár - Bereg megyei Kórházak és Egyetemi Oktatókórház
    Nyíregyháza, Hungary
  • Ziv Medical Center
    Zefat, 13100, Israel
  • Regionalny Szpital Specjalistyczny
    Grudziądz, 86-300, Poland
  • Szpital Uniwersytecki w Krakowie
    Kraków, 31-501, Poland
  • Dzienny Oddział Chemioterapii
    Racibórz, 47-400, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warszawa, 02-106, Poland
09

References and documents

Publications

  • Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Rostom M, Bhat G, Choi MR, Reddy G, Tedesco KL, Agajanian R, Lang I, Schwartzberg LS. An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer. Cancer Med. 2018 May;7(5):1660-1669. doi: 10.1002/cam4.1388. Epub 2018 Mar 23. PubMed 29573207 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Aug 2014, 16 months.

Results were first posted in Apr 2022, 7 years 8 months after primary completion. A results delay was requested in Jan 2020.

Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Nov 12, 2012
StartActual
Mar 25, 2013
Primary completionActual
Aug 12, 2014
CompletionActual
Aug 12, 2014
Results delay requested
Jan 23, 2020
Results first posted
Apr 15, 2022
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01724866
Responsible party
Sponsor
First posted
Nov 12, 2012
Start date
Mar 25, 2013
Primary completion
Aug 12, 2014
Completion
Aug 12, 2014
Results posted
Apr 15, 2022
Last update
Apr 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflapegrastim · Pegfilgrastim

Start the discussion